Depo-Provera has been used by millions of women worldwide as a long-acting injectable contraceptive. In recent years, however, scientific research has raised very important questions about the association between prolonged use of injectable medroxyprogesterone acetate, the active ingredient in Depo-Provera, and the development of meningioma, a type of tumour that occurs in the tissues surrounding the brain and spinal cord.
Where was the FDA, is the question? Why was is approved as safe?
This is a serious subject. The evidence deserves careful attention, but it is equally important to separate established scientific findings from exaggerated claims.
A significant association has been identified: There are large observational studies which have reported a big association between injectable medroxyprogesterone acetate and an increased risk of intracranial meningioma. One large US study reported a relative risk of 2.43 among users of depot medroxyprogesterone acetate, equivalent to a 143% higher relative risk compared with the control group studied. This should concern anyone using it.
The 143% figure requires careful interpretation: A 143% increase in relative risk does not mean that 143% of women using Depo-Provera will develop a brain tumour. Risk describes the difference between groups. The absolute risk for an individual woman remains considerable.
Longer exposure is particularly important: Research states that the association between injectable medroxyprogesterone acetate and meningioma is more significant with prolonged exposure. The studies have identified stronger associations among women who had used the medication for several years. How did this drug pass FDA Approval
What exactly is a meningioma? A meningioma develops from the meninges, the protective layers of tissue surrounding the brain and spinal cord. Many meningiomas are classified as benign or non-cancerous, but this does not mean they are harmless. A tumour inside the skull places pressure on the brain, nerves and blood vessels.
Depending on its location and size, a meningioma may cause headaches, seizures, visual disturbances, weakness, hearing problems, changes in balance, cognitive difficulties or other neurological symptoms. Some meningiomas require surgical removal, radiation treatment or long-term medical monitoring.
This is NOT based on one isolated study: Research from different populations has raised similar concerns about prolonged exposure to injectable medroxyprogesterone acetate and meningioma. When similar safety signals emerge across large studies and populations, they require serious scientific and regulatory attention.
Regulatory information has changed: However people are blindly trusting the doctor, NOT reading the tiny print. Product information for medroxyprogesterone acetate contraceptive injections has evolved to include information concerning meningioma and the association with repeated or prolonged exposure, within the small print. This reflects the importance of emerging safety information and the need for healthcare professionals and patients to be aware of potential risks. But why is it still a prescribed medication?
Legal claims are increasing: Women diagnosed with meningioma after using Depo-Provera have filed legal claims alleging that they were not adequately warned about the potential risks.
Women deserve clear and honest information: The most important issue is informed decision-making. Women should have access to understandable information about both the benefits and risks of medications they use, particularly when treatment may continue for years.
Every medication involves a balance between benefits and potential harms. For women who have used injectable medroxyprogesterone acetate over an extended period, the emerging evidence regarding meningioma is relevant information that deserves discussion with an appropriately qualified healthcare professional.
In my opinion, it should be withdrawn.
The bottom line: Scientific studies have identified an association between injectable medroxyprogesterone acetate and an increased relative risk of meningioma, with prolonged exposure appearing to be an important factor. A reported 143% increase refers to big risk Meningiomas can cause serious neurological consequences depending on their size and location. Regulatory information has evolved as scientific evidence has developed, while legal claims relating to alleged injuries continue through the courts.
The evidence surrounding Depo-Provera and meningioma deserves serious, yet the FDA refuse to withdraw it, you have to ask the question why?
